Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115374 | 1.00 | MMP8 (0.31) | MMP8CPB2 | |
| SCHEMBL6220401 | 0.72 | ALDH1A1 (0.36) | MMP8CPB2 | |
| SCHEMBL4820850 | 0.70 | — | — | |
| SCHEMBL4820834 | 0.70 | — | — | |
| SCHEMBL803804 | 0.68 | ALDH1A1 (0.43) | MMP8CPB2 | |
| SCHEMBL13537856 | 0.68 | ALDH1A1 (0.43) | MMP8CPB2 | |
| SCHEMBL803891 | 0.68 | ALDH1A1 (0.43) | MMP8CPB2 | |
| SCHEMBL13817690 | 0.68 | L3MBTL1 (0.47) | MMP8 | |
| SCHEMBL6625127 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL4820807 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546603-B2 | Substituted cyclopentanes having prostaglandin activity | ALLERGAN, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120178798-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8158676-B2 | Substituted cyclopentanes having prostaglandin activity | ALLERGAN, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090143461-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178798-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | MMP8 118/4885CPB2 644/4885 |
| US-20090143461-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | MMP8 118/4885CPB2 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.